9 Years vs. 13: The Problem With the Pill Penalty
Why does a small molecule medicine get nine years on the market before Medicare negotiation while a biologic gets 13? And what does that four-year difference mean for the medicines that do get developed?
For 9/13 Day, the Making Medicine Podcast is revisiting some of our most important conversations about the pill penalty and its impact on biotech investment, drug development and patients.
Under the Inflation Reduction Act, small molecule medicines become eligible for Medicare drug price setting after nine years, compared with 13 years for biologics. That difference may sound small, but…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.